Servicio Andaluz De Salud | Date: 2015-12-21
The invention relates to the use of antioxidants such as, ascorbic acid (Vitamin C), Tocopherol (Vitamin E), vitamin A and polyphenols, for the treatment of cognitive and behavioural disorders in patients with Fragile X syndrome. Specifically, the invention relates to the use of said antioxidants in a pre-determined concentration in a therapeutic doses, in order to obtain the greatest amount of antioxidants possible in all the tissues of the organism, so as to eliminate the excess free radicals produced in the cells and to treat the aforementioned cognitive and behavioural disorders in patients with Fragile X syndrome.
Servicio Andaluz De Salud and University of Seville | Date: 2013-06-05
The invention describes a method for obtaining data useful for the diagnosis, prognosis and classification of individuals with chronic obstructive pulmonary disease (COPD) and/or lung cancer, diagnostic kit, device and uses thereof for the diagnosis, prognosis and classification of patients as a) individuals with no COPD or lung cancer, b) individuals with COPD, c) individuals with adenocarcinoma, d) individuals with COPD and adenocarcinoma, or e) individuals with COPD and squamous carcinoma
Servicio Andaluz De Salud | Date: 2012-10-11
A composition based on a poly-organosiloxane which is suitable for its use as a bolus in radiotherapy treatments. Other possible uses of this composition are the production of an immobilizing mask for radio surgery or cranial stereotaxy treatments and the production of an intraoral depressor.
Servicio Andaluz De Salud | Date: 2012-12-14
A method for obtaining useful data for the determination of an individuals risk of suffering from severe sensorineural hearing loss, preferably in Mnires disease, primers useful in the determination and kit comprising same.
Servicio Andaluz De Salud | Date: 2012-12-13
The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide NK1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor. The result of the alteration to the peritumoral environment is a reduction in the size of the tumor, the prevention of its development and, optionally, the induction of its disappearance. The invention also relates to pharmaceutical compositions containing said peritumoral-environment-altering agents, either alone or combined with at least one other active ingredient, for the treatment of cancer.